Pathogenesis of colorectal carcinoma and therapeutic implications: The roles of the ubiquitin-proteasome system and Cox-2: Cancer

Journal of Cellular and Molecular Medicine

Volumn 11, Issue 2, 2007, Pages 252-285

  Voutsadakis, Ioannis A ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Adenomatous polyposis coli; Carcinogenesis; Cyclooxygenase 2; Non steroidal anti inflammatory drugs; Proteasome inhibition; Ubiquitin proteasome system

Indexed keywords

CYCLOOXYGENASE 2; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEASOME; UBIQUITIN;

BIOLOGICAL MODEL; CARCINOMA; COLORECTAL TUMOR; HUMAN; METABOLISM; REVIEW;

CARCINOMA; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; MODELS, BIOLOGICAL; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 34247887546     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2007.00032.x     Document Type: Review

References (298)

1. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001 1 : 55 67.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 61 : 759 67.
3. Hisamuddin IM, Yang VW. Molecular genetics of colorectal cancer: an overview. Cur Colorectal Cancer Rep. 2006 2 : 53 9.
4. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003 348 : 919 32.
5. Loeb LA. A mutator phenotype in cancer. Cancer Res. 2001 61 : 3230 9.
6. Kondo Y, Issa J-PJ. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004 23 : 29 39.
7. Shen L, Issa J-PJ. Epigenetics in colorectal cancer. Curr Opin Gastroenterol. 2002 18 : 68 73.
8. Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, Campan M, Laird PW, Loda M, Fuchs CS. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut. 2006 55 : 1000 6.
9. Liu CH, Chang S-H, Narko K, Trifan OC, Wu M-T, Smith E, Haudenschild C, Lane TF, Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001 276 : 18563 9.
10. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R. A randomized trial of aspirin to prevent colorectal adenoma in patients with previous colorectal cancer. N Engl J Med. 2003 348 : 883 90.
11. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeowm-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003 348 : 891 9.
12. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med. 2003 348 : 879 80.
13. Clevers H. Wnt breakers in colon cancer. Cancer Cell. 2004 5 : 5 6.
14. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003 116 : 1175 86.
15. Ilyas M. Wnt signalling and the mechanistic basis of tumour development. J Pathol. 2005 205 : 130 44.
16. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997 16 : 3797 804.
17. Easwaran V, Song V, Polakis P, Byers S. The ubiquitin- proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of β-catenin-lymphocyte enhancerbinding factor signalling. J Biol Chem. 1999 274 : 16641 5.
18. Taya S, Yamamoto T, Kanai-Azuma M, Wood SA, Kaibuchi K. The deubiquitinating enzyme Fam interacts with and stabilizes beta-catenin. Genes Cells. 1999 4 : 757 67.
19. Li H, Pamukcu R, Thompson WJ. β-catenin signaling. Therapeutic strategies in oncology. Cancer Biol Ther. 2002 1 : 621 5.
20. Choi J, Park SY, Costantini F, Jho E-h, Joo C-K. Adenomatous polyposis coli is down-regulated by the ubiquitin-proteasome pathway in a process facilitated by axin. J Biol Chem. 2004 279 : 49188 98.
21. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 1999 96 : 5522 7.
22. Wong NACS, Pignatelli M. β-catenin-A linchpin in colorectal carcinogenesis? Am J Pathol. 2002 160 : 389 401.
23. Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AMC. Transcriptional activation of cyclooxygenase- 2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res. 1999 59 : 1572 7.
24. Levy L, Neuveut C, Renard CA, Charneau P, Branchereau S, Gauthier F, Van Nhieu JT, Cherqui D, Petit-Bertron AF, Mathieu D, Buendia MA. Transcriptional activation of interleukin-8 by betacatenin- Tcf4. J Biol Chem. 2002 277 : 42386 93.
25. Rockman SP, Currie SA, Ciavarella M, Vincan E, Dow C, Thomas RJS, Phillips WA. Id2 is a target of the β-catenin/T cell factor pathway in colon carcinoma. J Biol Chem. 2001 276 : 45113 9.
26. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO, Buhr HJ, Hanski C. Target genes of β-catenin/T cellfactor/lymphoid-enhancer-factor signalling in human colorectal carcinomas. Proc Natl Acad Sci USA. 1999 96 : 1603 8.
27. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol. 2002 2 : 8.
28. Dihlmann S, Kloor M, Fallsehr C, von Knebel Doeberitz M. Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells. Carcinogenesis. 2005 26 : 1503 12.
29. He T-C, Chan TA, Vogelstein B, Kinzler KW. PPARγ is an APC-regulated target of Non-steroidal antiinflammatory drugs. Cell. 1999 99 : 335 45.
30. Conacci-Sorrell ME, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze'ev A. Nr-CAM is a target gene of the β-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev. 2002 16 : 2058 72.
31. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, Ben-Ze'ev A. L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol. 2005 168 : 633 42.
32. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, van de Wetering M, Clevers H, Schlag PH, Birchmeier W, Behrens J. Negative feedback loop of wnt signaling through upregulation of conductin/ axin2 in colorectal and liver tumors. Mol Cell Biol. 2002 22 : 1184 93.
33. Boon EMJ, Van Der Neut R, van de Wetering M, Clevers H, Pals ST. Wnt signaling regulates expression of the receptor tyrosine kinase Met in colorectal cancer. Cancer Res. 2002 62 : 5126 8.
34. Battle E, Henderson JT, Beghtel H, Van Den Born MM, Sancho E, Huls G, Meeldijk J, Robertson J, van de Wetering M, Pawson T, Clevers H. β-catenin and TCF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/Ephrin B. Cell. 2002 111 : 251 63.
35. van de Wetering M, Sancho E, Verweij C, de Lau N, Oving I, Hurlstone A, Van Der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moerer P, Van Den Born M, Soete G, Pals S, Eilers M, Medema R, Clevers H. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell. 2002 111 : 241 50.
36. Spigelman VS, Slaga TJ, Pagano M, Minamoto T, Ronai Z, Fuchs SY. Wnt/β-catenin signalling induces the expression and activity of βTrCP ubiquitin ligase receptor. Mol Cell. 2000 5 : 877 82.
37. Sansom OJ, Reed KR, van de Wetering M, Muncan V, Winton DJ, Clevers H, Clarke AR. Cyclin D1 is not an immediate target of β-catenin following Apc loss in the intestine. J Biol Chem. 2005 280 : 28463 7.
38. Shtutman M, Zhurinsky J, Oren M, Levina E, Ben-Ze'ev A. PML is a target gene of β-catenin and plakoglobin, and coactivates β-catenin-mediated transcription. Cancer Res. 2002 62 : 5947 54.
39. Steigerwald K, Behbehani GK, Combs KA, Barton MC, Groden J. The APC tumor suppressor promotes transcription-independent apoptosis in vitro. Mol Cancer Res. 2005 3 : 78 89.
40. Kawasaki Y, Senda T, Ishidate T, Koyama R, Morishita T, Iwayama Y, Higuchi O, Akiyama T. Asef, a link between the tumor suppressor APC and G-protein signaling. Science. 2000 289 : 1194 7.
41. Moon RT, Bowerman B, Boutros M, Perrimon N. The promise and perils of Wnt signalling through _- catenin. Science. 2002 296 : 1644 6.
42. Murray NR, Davidson LA, Chapkin RS, Gustafson WC, Schattenberg DG, Fields AP. Overexpression of protein kinase C βII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol. 1999 145 : 699 711.
43. Benetti R, Copetti T, Dell'Orso S, Melloni E, Brancolini C, Monte M, Schneider C. The calpainsystem involved in the constitutive regulation of β-catenin signalling functions. J Biol Chem. 2005 280 : 22070 80.
44. Roura S, Miravet S, Piedra J, García de Herreros A, Duñach M. Regulation of E-cadherin/catenin association by tyrosine phosphorylation. J Biol Chem. 1999 274 : 36734 40.
45. Sadot E, Conacci-Sorrell M, Zhurinsky J, Shnizer D, Lando Z, Zharhary D, Kam Z, Ben-Ze'ev A, Geiger B. Regulation of S33/S37 phosphorylated _- catenin in normal and transformed cells. J Cell Sci. 2002 115 : 2771 80.
46. Deng J, Miller SA, Wang H-Y, Xia W, Wen Y, Zhou BP, Li Y, Lin S-Y, Hung M-C. β-catenin interacts with and inhibits NF-κB in human colon and breast cancer. Cancer Cell. 2002 2 : 323 34.
47. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature. 2000 406 : 86 90.
48. Ilyas M, Tomlinson IPM, Rowan A, Pignatelli M, Bodmer WF. β-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA. 1997 94 : 10330 4.
49. Samowitz WS, Powers MD, Spirio LN, Nollet F, van Roy F, Slattery ML. β-catenin mutations are more frequent in small colorectal adenomas than in larger adenomas and invasive carcinomas. Cancer Res. 1999 59 : 1442 4.
50. Smit L, Baas A, Kuipers J, Korswagen H, van de Wetering M, Clevers H. Wnt activates the Tak1/Nemo-like kinase pathway. J Biol Chem. 2004 279 : 17232 40.
51. Essers MAG, de Vries-Smits LMM, Barker N, Polderman PE, Burgering BMT, Korswagen HC. Functional interaction between β-catenin and FOXO in oxidative stress signalling. Science. 2005 308 : 1181 4.
52. Bowerman B. Oxidative stress and cancer: a β-catenin convergence. Science. 2005 308 : 1119 20.
53. Damalas A, Ben-Ze'ev A, Simcha I, Shtutman M, Martinez Leal JF, Zhurinsky J, Geiger B, Oren M. Excess β-catenin promotes accumulation of transcriptionally active p53. EMBO J. 1999 18 : 3054 63.
54. Damalas A, Kahan S, Shtutman M, Ben-Ze'ev A, Oren M. Deregulated β-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J. 2001 20 : 4912 22.
55. Andreyev HJN, Norman AR, Cunningham D, Oates JR, Clarke PA, for the RASCAL Group. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst. 1998 90 : 675 84.
56. Bos JL. Ras oncogene in human cancer: a review. Cancer Res. 1989 49 : 4682 9.
57. Kerkhoff E, Rapp UR. Cell cycle targets of Ras/Raf signalling. Oncogene. 1998 17 : 1457 62.
58. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005 6 : 322 7.
59. Fujita T, Washio K, Takabatake D, Takahashi H, Yoshitomi S, Tsukuda K, Ishibe Y, Ogasawara Y, Doihara H, Shimizu N. Proteasome inhibitors can alter the signaling pathways and attenuate the P-glycoprotein- mediated multidrug resistance. Int J Cancer. 2005 117 : 670 82.
60. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franken TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998 282 : 1318 21.
61. Aoki M, Jiang H, Vogt PK. Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. Proc Natl Acad Sci USA. 2004 101 : 13613 7.
62. Thomas GV. mTOR and cancer: reason for dancing at the crossroads? Cur Opin Genet Dev. 2006 16 : 78 84.
63. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA. 1999 96 : 4240 5.
64. Vivanco I, Sawyers CL. The phosphatidylinositol 3- kinase-akt pathway in human cancer. Nat Rev Cancer. 2002 2 : 489 501.
65. Cullen PJ, Lockyer PJ. Integration of calcium and Ras signalling. Nature Rev Mol Cell Biol. 2002 3 : 339 48.
66. Attisano L, Wrana JL. Signal transduction by the TGF-β superfamily. Science. 2002 296 : 1646 7.
67. Wakefield LM, Roberts AB. TGF-β signaling: positive and negative effects on tumorigenesis. Cur Opin Genet Dev. 2002 12 : 22 9.
68. Saha D, Datta PK, Beauchamp RD. Oncogenic Ras represses Transforming Growth Factor-β signalling by degrading tumor suppressor Smad4. J Biol Chem. 2001 276 : 29531 7.
69. Xu J, Attisano L. Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor β signalling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 2000 97 : 4820 5.
70. Lo RS, Wotton D, Massagué J. Epidermal growth factor signaling viaRas controls the Smad transcriptional co-repressor TGIF. EMBO J. 2001 20 : 128 6.
71. Iglesias M, Frontelo P, Gamallo C, Quintanilla M. Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas. Oncogene. 2000 19 : 4134 45.
72. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005 23 : 2078 93.
73. Schepers H, Wierenga ATJ, Eggen BJL, Vellenga E. Oncogenic Ras blocks transforming growth factor- β-induced cell-cycle arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway. Exp Hematol. 2005 33 : 747 57.
74. Tadlock L, Yamagiwa Y, Hawker J, Marienfeld C, Patel T. Transforming growth factor-_ inhibition of proteasomal activity: a potential mechanism of growth arrest. Am J Cell Physiol. 2003 285 : C277 85.
75. Furuhashi M, Yagi K, Yamamoto H, Furukawa Y, Shimada S, Nakamura Y, Kikuchi A, Miyazono K, Kato M. Axin facilitates Smad3 activation in the transforming growth factor _ signaling pathway. Mol Cell Biol. 2001 21 : 5132 41.
76. Labbé E, Letamendia A, Attiasano L. Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signalling by the transforming growth factor-beta and wnt pathways. Proc Natl Acad Sci USA. 2000 97 : 8358 63.
77. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. Intestinal tumorigenesis in compound mutant mice of both DPC4 (Smad4) and Apc genes. Cell. 1998 92 : 645 56.
78. Zavadil J, Bitzer M, Liang D, Yang Y-C, Massimi A, Kneitz S, Piek E, Böttinger EP. Genetic programs of epithelial cell plasticity directed by transforming growth factor-β. Proc Natl Acad Sci USA. 2001 98 : 6686 91.
79. Yang Y-C, Piek E, Zavadil J, Liang D, Xie D, Heyer J, Pavlidis P, Kucherlapati R, Roberts AB, Böttinger EP. Hierarchical model of gene regulation by transforming growth factor-β. Proc Natl Acad Sci USA. 2003 100 : 10269 74.
80. Blanchette F, Rivard N, Rudd P, Grondin F, Attisano L, Dubois CM. Cross talk between p42/p44 MAP Kinase and Smad pathways in transforming growth factor-_1-induced furin gene transactivation. J Biol Chem. 2001 276 : 33986 94.
81. Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M, Hishima T, Koike M, Shitara N, Iwama T, Utsunomiya J, Kuroki T, Mori T. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene. 1999 18 : 3098 103.
82. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B. Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res. 1995 55 : 5548 50.
83. Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, Kinzler KW, Vogelstein B, Willson JK. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res. 1999 59 : 320 4.
84. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H, Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 1996 86 : 543 52.
85. Yu J, Zhang L. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Com. 2005 331 : 851 8.
86. Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B. Identification and classification of p53- regulated genes. Proc Natl Acad Sci USA. 1999 96 : 14517 22.
87. Roperch J-P, Lethrone F, Prieur S, Piouffre L, Israeli D, Tuynder M, Nemani M, Pasturaud P, Gendron M-C, Dausset J, Oren M, Amson RB, Telerman A. SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: identification of common effectors with p53 and p21Waf1. Proc Natl Acad Sci USA. 1999 96 : 8070 3.
88. Amson RB, Nemani M, Roperch JP, Israeli D, Bougueleret L, LeGall I, Medhioub M, Linares-Cruz G, Lethrosne F, Pasturaud P, Piouffre L, Prieur S, Susini L, Alvaro V, Millasseau P, Guidicelli C, Bui H, Massart C, Cazes L, Dufour F, Bruzzoni-Giovanelli H, Owadi H, Hennion C, Charpak G, Dausset J, Calvo F, Oren M, Cohen D, Telerman A. Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the drosophila seven in absentia gene. Proc Natl Acad Sci USA. 1996 93 : 3953 7.
89. Chen D, Kon N, Li M, Zhang W, Qin J, Gu W. ARFBP1/ Mule is a critical mediator of the ARF tumor suppressor. Cell. 2005 121 : 1071 83.
90. Zhong Q, Gao W, Du F, Wang X. Mule ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell. 2005 121 : 1085 95.
91. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, Parant JM, Lozano G, Hakem R, Benchimol S. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003 112 : 779 91.
92. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, O'Rourke K, Koeppen H, Dixit VM. The ubiquitin ligase COP is a critical negative regulator of p53. Nature. 2004 429 : 86 92.
93. Shmueli A, Oren M. Life, death, and ubiquitin: taming the mule. Cell. 2005 121 : 963 5.
94. Kohn KW, Pommier Y. Molecular interaction map of the p53 and mdm2 logic elements, which control the off-on switch of p53 in response to DNA damage. Biochem Biophys Res Com. 2005 331 : 816 27.
95. Coutts AS, La Thangue NB. The p53 response: emerging levels of co-factor complexity. Biochem Biophys Res Com. 2005 331 : 778 85.
96. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL, Matsunami N. Siah-1 mediates a novel β-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell. 2001 7 : 927 36.
97. Nakayama K, Ronai Z. Siah new players in the cellular response to hypoxia. Cell Cycle. 2004 : 3 : 1345 7.
98. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat. 2003 21 : 271 6.
99. Jänne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med. 2000 342 : 1960 8.
100. Wolf DH, Hilt W, Sommer T. Death gives birth to life: the essential role of the ubiquitin-proteasome system in biology. Biochim Biophys Acta. 2004 1695 : 1 2.
101. Hoeller D, Hecker C-M, Dikic I. Ubiquitin and ubiquitin- like proteins in cancer pathogenesis. Nat Rev Cancer. 2006 6 : 776 88.
102. Miller J, Gordon C. The regulation of proteasome degradation by multi-ubiquitin chain binding proteins. FEBS Lett. 2005 579 : 3224 30.
103. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 2005 23 : 4776 89.
104. Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, Hohfeld J, Patterson C. CHIP is a U-box-dependent E3 ubiquitin ligase. J Biol Chem. 2001 276 : 42938 44.
105. Pickart CM. Back to the future with ubiquitin. Cell. 2004 116 : 181 90.
106. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nature Rev Mol Cell Biol. 2005 6 : 599 609.
107. Cyr DM, Höhfeld J, Patterson C. Protein quality control; U-box-containing E3 ubiquitin ligases join the fold. Trends Biochem Sci. 2002 27 : 368 75.
108. Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta. 2004 1695 : 189 207.
109. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J, Gu W. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature. 2002 416 : 648 53.
110. Verma R, Aravind L, Oania R, McDonald WH, Yates JR 3rd., Koonin EV, Deshaies RJ. Role of Rpn11 metalloprotease motif in deubiquitination and degradation by the 26S proteasome. Science. 2002 298 : 611 5.
111. Yao T, Cohen RE. A cryptic protease couples deubiquitination and degradation by the 26S proteasome. Nature. 2002 419 : 403 7.
112. Hanson PI, Whiteheart SW. AAA+ proteins: have engine, will work. Nature Rev Mol Cell Biol. 2005 6 : 519 29.
113. DeMartino GN, Slaughter CA. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem. 1999 274 22123 6.
114. Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002 16 : 433 43.
115. Wolf DH, Hilt W. The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochim Biophys Acta. 2004 1695 : 19 31.
116. Kisselev AF, Callard A, Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem. 2006 281 : 8582 90.
117. Vial E, Marshall CJ. Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J Cell Sci. 2003 116 : 4957 63.
118. Asher G, Tsvetkov P, Kahana C, Shaul Y. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppresors p53 and p73. Genes Dev. 2005 19 : 316 21.
119. Zhu Z, Ramos J, Kampa K, Adimoolam S, Sirisawad M, Yu Z, Chen D, Naumovski L, Lopez CD. Control of ASPP2/53BP2L protein levels by proteasomal degradation modulates p53 apoptotic function. J Biol Chem. 2005 280 : 34473 80.
120. Zhurinsky J, Shtutman M, Ben-Ze'ev A. Plakoglobin and β-catenin: protein interactions, regulation and biological roles. J Cell Sci. 2000 113 : 3127 39.
121. Alvarez-Castelao B, Castano JG. Mechanism of direct degradation of IκBβ by 20S proteasome. FEBS Lett. 2005 579 : 4797 802.
122. Dupont S, Zacchigna L, Cordenonsi M, Soligo S, Adorno M, Rugge M, Piccolo S. Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell. 2005 121 : 87 99.
123. Mori S, Keiji T, Omura S, Saito Y. Degradation process of ligand-stimulated Platelet-derived growth factor β-receptor involves ubiquitin-proteasome proteolytic pathway. J Biol Chem. 1995 270 : 29447 52.
124. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome- dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA. 2000 97 : 3850 5.
125. Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, Davis JJ, Chiao PJ, Fang B. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene. 2005 24 : 4993 9.
126. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005 4 : 443 9.
127. Tao G-Z, Rott LS, Lowe AW, Omary MB. Hyposmotic stress induces cell growth arrest via proteasome activation and cyclin/cyclin-dependent kinase degradation. J Biol Chem. 2002 277 : 19295 303.
128. Desai SD, Li T-K, Rodriguez-Bauman A, Rubin EH, Liu LF. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. 2001 61 : 5926 32.
129. Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. 2000 60 : 2429 34.
130. Liu Z, Lu H, Shi H, Du Y, Yu J, Gu S, Chen X, Liu KJ, Hu CA. PUMA overexpression induces reactive oxygen species generation and proteasome-mediated stathmin degradation in colorectal cancer cells. Cancer Res. 2005 65 : 1647 54.
131. Nakayama K, Frew IJ, Hagensen M, Skals M, Habelhah H, Bhoumik A, Kadoya T, Erdjument-Bromage H, Tempst P, Frappell PB, Bowtell DD, Ronai Z. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1_ abundance, and modulates physiological responses to hypoxia. Cell. 2004 117 : 941 52.
132. Glickman MH, Raveh D. Proteasome plasticity. FEBS Lett. 2005 579 : 3214 23.
133. Mikalsen T, Johannesen M, Moens U. Sequenceand position-dependent tagging protects extracellular- regulated kinase 3 protein from 26S proteasomemediated degradation. Int J Biochem Cell Biol. 2005 37 : 2513 20.
134. Adachi M, Katsumura KR, Fujii K, Kobayashi S, Aoki H, Matsuzaki M. Proteasome-dependent decrease in Akt by growth factors in vascular smooth muscle cells. FEBS Lett. 2003 554 : 77 80.
135. Demontis S, Rigo C, Piccinin S, Mizzau M, Sonego M, Fabris M, Brancolini C, Maestro R. Twist is substrate for caspase cleavage and proteasome-mediated degradation. Cell Death Differ. 2006 13 : 335 45.
136. Hu G, Zhang S, Vidal M, La Baer J, Xu T, Fearon ER. Mammalian homologs of seven in absentia regulate DCC via the ubiquitin-proteasome pathway. Genes Dev. 1997 11 : 2701 14.
137. Lee TH, Perrem K, Harper JW, Lu KP, Zhou XZ. The F-box protein FBX4 targets PIN2/TRF1 for ubiquitinmediated degradation and regulates telomere maintenance. J Biol Chem. 2006 281 : 759 68.
138. Bhanumathy CD, Nakao SK, Joseph SK. Mechanism of proteasomal degradation of inositol trisphosphate receptors in CHO-K1 cells. J Biol Chem. 2006 281 : 3722 30.
139. Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S. Peroxisome Proliferator-activated Receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and Estrogen Receptor α in MCF-7 breast cancer cells. Cancer Res. 2003 63 : 958 64.
140. Ozdamar B, Bose R, Barrios-Rodiles M, Wang HR, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science. 2005 307 : 1603 9.
141. Chen ZJ. Ubiquitin signalling in the NF-κB pathway. Nature Cell Biol. 2005 7 : 758 65.
142. Fong A, Shao-Cong S. Genetic evidence for the essential role of β-Transducin repeat-containing protein in the inducible processing of NF-κB2/p100. J Biol Chem. 2002 277 : 22111 4.
143. Lang V, Janzen J, Zvi Fischer G, Soneji Y, Beinke S, Salmeron A, Allen H, Hay RT, Ben-Neriah Y, Ley SC. βTrCP-mediated proteolysis of NF-κB1 p105 requires phosphorylation of p105 serines 927 and 932. Mol Cell Biol. 2003 23 : 402 13.
144. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, Chen ZL. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature. 2001 412 : 346 51.
145. Ougolkov A, Zhang B, Yamashita K, Bilim V, Mai M, Fuchs SY, Minamoto T. Associations among β-TrCP, an E3 ubiquitin ligase receptor, β-catenin, and NF-κB in colorectal cancer. J Natl Cancer Inst. 2004 96 : 1161 70.
146. Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, Mishra G, Moldawer LL, Copeland EM 3rd., Mackay S. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery. 2001 130 : 363 9.
147. Yu H-G, Yu L-L, Yang Y, Luo H-S, Yu J-P, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F. Increased expression of RelA/Nuclear factor- κB protein correlates with colorectal tumorigenesis. Oncology. 2003 65 : 37 45.
148. Shumway SD, Maki M, Miyamoto S. The PEST domain of IκBα is necessary and sufficient for in vitro degradation by μ-calpain. J Biol Chem. 1999 274 : 30874 81.
149. Reed JC. Mechanisms of apoptosis. Am J Pathol. 2000 157 : 1415 30.
150. Voutsadakis IA. Apoptosis and the pathogenesis of lymphoma. Acta Oncol. 2000 39 : 151 6.
151. Vaux DL, Silke J. IAPs, RINGs and ubiquitylation. Nature Rev Mol Cell Biol. 2005 6 : 287 97.
152. Ni T, Li W, Zou F. The ubiquitin ligase ability of IAPs regulates apoptosis. IUBMB Life. 2005 57 : 779 85.
153. Yang Y, Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J. 2003 17 : 790 9.
154. Shiozaki EN, Chai J, Rigotti DJ, Riedl SJ, Srinivasula SM, Alnemri ES, Fairman R, Shi Y. Mechanism of XIAP-mediated inhibition of caspase- 9. Mol Cell. 2003 11 : 519 27.
155. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, Lee R-A, Robbins PD, Fernandes-Alnemri T, Shi Y, Alnemri ES. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 2001 410 : 112 6.
156. MacFarlane M, Merrison W, Bratton SB, Cohen GM. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem. 2002 277 : 36611 6.
157. Vaux DL, Silke J. HtrA2/Omi, a sheep in wolf's clothing. Cell. 2003 115 : 251 3.
158. Tansey WP. Death, destruction, and the proteasome. N Engl J Med. 2004 351 : 393 4.
159. Hegde R, Srinivasula SM, Datta P, Madesh M, Wassell R, Zhang ZJ, Cheong NE, Nejmeh J, Fernandes-Alnemri T, Hoshino S, Alnemri ES. The polypeptide chain-releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein. J Biol Chem. 2003 278 : 38699 706.
160. Sun X-M, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM. Caspase activation inhibits proteasome function during apoptosis. Mol Cell. 2004 14 : 81 93.
161. Adrain C, Creagh EM, Cullen SP, Martin SJ. Caspase-dependent inactivation of proteasome function during programmed cell death in drosophilaand man. J Biol Chem. 2004 279 : 36923 30.
162. Friedman J, Xue D. To live or die by the sword: the regulation of apoptosis by the proteasome. Dev Cell. 2004 7 : 460 1.
163. Silke J, Kratina T, Chu D, Ekert PG, Day CL, Pakusch M, Huang DCS, Vaux DL. Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc Natl Acad Sci USA. 2005 102 : 16182 7.
164. Chen F, Chang D, Goh M, Klibanov SA, Ljungman M. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Diff. 2000 11 : 239 46.
165. Ravizza R, Gariboldi MB, Passarelli L, Monti E. Role of the p53/p21 system in the response of human colon carcinoma cells to doxorubicin. BMC Cancer. 2004 4 : 92.
166. Castro A, Vigneron S, Lorca T, Labbé J-C. La mitose sous surveillance. Med Sci. 2003 19 : 309 17.
167. Vodermaier HC. APC/C and SCF: controlling each other and the cell cycle. Cur Biol. 2004 14 : R787 96.
168. Kops GJPL, Weaver BAA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005 5 : 773 85.
169. Jackson PK. Linking tumor suppression, DNA damage and the anaphase-promoting complex. Trends Cell Biol. 2004 14 : 331 4.
170. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome- dependent degradation of the cyclindependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 1997 3 : 231 4.
171. Thomas GV, Szigeti K, Murphy M, Draetta G, Pagano M, Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastases. Am J Pathol. 1998 153 : 681 7.
172. Shapira M, Ben-Izhak O, Linn S, Futerman B, Minkov I, Hershko DD. The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma. Cancer. 2005 103 : 1336 46.
173. Hershko DD, Shapira M. Prognostic role of p27Kip1 deregulation in colorectal cancer. Cancer. 2006 107 : 668 75.
174. Charalambous MP, Maihöfner C, Bhambra U, Lightfoot T, Gooderham NJ, Colorectal Cancer Study Group. Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-κB and IκB kinase-α in human colorectal cancer epithelial cells. Br J Cancer. 2003 88 : 1598 604.
175. Hochwald SN, Lind DS, Malaty J, Copeland EM 3rd., Moldawer LL, MacKay SL. Antineoplastic therapy in colorectal cancer through proteasome inhibition. Am Surg. 2003 69 : 15 23.
176. Gupta RA, DuBois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001 1 : 11 21.
177. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control. 2002 9 : 28 35.
178. McEntee MF, Cates JM, Neilsen N. Cyclooxygenase- 2 expression in spontaneous intestinal neoplasia of domestic dogs. Vet Pathol. 2001 39 : 428 36.
179. Araki Y, Okamura S, Perwez Hussain S, Nagashima M, He P, Shiseki M, Miura K, Harris CC. Regulation of cyclooxygenase-2 expression by the Wnt and Ras pathways. Cancer Res. 2003 63 : 728 34.
180. Chun K-S, Surh Y-J. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol. 2004 68 : 1089 100.
181. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005 23 : 2840 55.
182. Castellone MD, Teramoto H, Gutkind JS. Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection. Cancer Res. 2006 66 : 11085 8.
183. Syeda F, Grosjean J, Houliston RA, Keogh RJ, Carter T, Paleolog E, Wheeler-Jones CPD. Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells requires co-operation between mitogen-activated protein kinase and NF-κB pathways. J Biol Chem. 2006 281 : 11792 804.
184. Matsuura H, Sakaue M, Subbaramaiah K, Kamitani H, Eling TE, Dannenberg AJ, Tanabe T, Inoue H, Arata J, Jetten AM. Regulation of Cyclooxygenase-2 by interferon γ and transforming growth factor α in normal human epidermal keratinocytes and squamous carcinoma cells. J Biol Chem. 1999 274 : 29138 48.
185. Yan Z, Subbaramaiah K, Camilli T, Zhang F, Tanabe T, McCaffrey TA, Dannenberg AJ, Weksler BB. Benzo[α]pyrene induces the transcription of cyclooxygenase-2 in vascular smooth muscle cells. J Biol Chem. 2000 275 : 4949 55.
186. Duque J, Díaz-Muñoz MD, Fresno M, Iñiguez MA. Up-regulation of cyclooxygenase-2 by interleukin-1β in colon carcinoma cells. Cell Signal. 2006 18 : 1262 9.
187. Yamaguchi K, Lantowski A, Dannenberg AJ, Subbaramaiah K. Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including Cox-2. J Biol Chem. 2005 280 : 32569 77.
188. Howe LR, Crawford HC, Subbaramaiah K, Hassell JA, Dannenberg AJ, Brown AMC. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J Biol Chem. 2001 276 : 20108 15.
189. Duque J, Fresno M, Iñiguez MA. Expression and function of the Nuclear Factor of Activated T cells in colon carcinoma cells. J Biol Chem. 2005 280 : 8686 93.
190. Meade EA, McIntyre TM, Zimmerman GA, Prescott SM. Peroxisome Proliferators enhance Cyclooxygenase- 2 expression in epithelial cells. J Biol Chem. 1999 274 : 8328 34.
191. Lefebvre A-M, Chen I, Desreumaux P, Najib J, Fruchart JC, Geboes K, Briggs M, Heyman R, Auwerx J. Activation of the peroxisome proliferatoractivated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med. 1998 4 : 1053 7.
192. Dixon DA, Balch GC, Kedersha N, Anderson P, Zimmerman GA, Beauchamp RD, Prescott SM. Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. J Exp Med. 2003 198 : 475 81.
193. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM. Post-transcriptional control of cyclooxygenase-2 gene expression. J Biol Chem. 2000 275 : 11750 7.
194. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (Cyclooxygenases)-1 and -2. J Biol Chem. 1996 271 : 33157 60.
195. Warner TD, Mitchell JA. Nonsteroidal anti-inflammatory drugs inhibiting prostanoid efflux: as easy as ABC? Proc Natl Acad Sci USA. 2003 100 : 9108 10.
196. Cutler NS, Graves-Deal R, LaFleur BJ, Gao Z, Boman BM, Whitehead RH, Terry E, Morrow JD, Coffey RJ. Stromal production of prostacyclin confers an antiapoptotic effect to colonic epithelial cells. Cancer Res. 2003 63 : 1748 51.
197. Ko SC, Chapple KS, Hawcroft G, Coletta PL, Markham AF, Hull MA. Paracrine cyclooxygenase- 2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells. Oncogene. 2002 : 21 : 7175 86.
198. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999 79 : 1193 226.
199. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001 108 : 25 30.
200. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem. 2001 276 : 18075 81.
201. Buchanan FG, Wang D, Bargiacchi F, DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003 278 : 35451 7.
202. Pai R, Soreghan B, Szabo I, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002 8 : 289 93.
203. Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, DuBois RN. Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor δ. Cancer Cell. 2004 6 : 285 95.
204. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferaratoractivated receptor-δ attenuates colon carcinogenesis. Nat Med. 2004 10 : 481 3.
205. Burdick AD, Kim DJ, Peraza MA, Gonzalez FJ, Peters JM. The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differantiation. Cell Signal. 2006 18 : 9 20.
206. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signalling axis. Science. 2005 310 : 1504 10.
207. Clevers H. Colon cancer- Understanding how NSAIDs work. N Engl J Med. 2006 354 : 761 3.
208. Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+mice. J Biol Chem. 2004 279 : 43261 72.
209. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006 108 : 804 11.
210. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. Tumor cyclooxygenase 2/prostaglandin E2 dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005 65 : 5211 20.
211. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, Sugimura T, Wakabayashi K. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res. 1999 59 : 5093 6.
212. Tran CP, Cook GA, Yeomans ND, Thim L, Giraud AS. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut. 1999 44 : 636 42.
213. Rodrigues S, Nguyen Q-D, Faivre S, Bruyneel E, Thim L, Westley B, May F, Flatau G, Mareel M, Gespach C, Emami S. Activation of cellular invasion by trefoil peptides and src is mediated cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J. 2001 15 : 1517 28.
214. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai H-H, Musiek ES, Milne GL, Katkuri S, DuBois RN. 15-hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005 280 : 3217 23.
215. Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JKV, Luo G, Hensold J, Tai H-H, Wilson K, Markowitz SD. 15-hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA. 2004 101 : 17468 73.
216. FitzGerald GA, Loll P. COX in a crystal ball: current status and future promise of prostaglandin research. J Clin Invest. 2001 107 : 1335 7.
217. Takeda H, Sonoshita M, Oshima H, Sugihara K, Chulada PC, Langenbach R, Oshima M, Taketo MM. Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res. 2003 63 : 4872 7.
218. Scorrano L, Penzo D, Petronilli V, Pagano F, Bernardi P. Arachidonic acid causes cell death through the mitochondrial permeability transition. J Biol Chem. 2001 276 : 12035 40.
219. Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA. 2000 97 : 11280 5.
220. Brash AR. Arachidonic acid as a bioactive molecule. J Clin Invest. 2001 107 : 1339 45.
221. Cao Y, Dave KB, Doan TP, Prescott SM. Fatty acid CoA ligase 4 is up-regulated in colon adenocarcinoma. Cancer Res. 2001 61 : 8429 34.
222. Sung YK, Hwang SY, Park MK, Bae HI, Kim WH, Kim J-C, Kim M. Fatty acid-CoA ligase 4 is overexpressed in human hepatocellular carcinoma. Cancer Sci. 2003 94 : 421 4.
223. Jayadev S, Hayter HL, Andrieu N, Gamard CJ, Liu B, Balu R, Hayakawa M, Ito F, Hannun YA. Phospholipase A2 is necessary for Tumor Necrosis Factor α-induced ceramide generation in L929 cells. J Biol Chem. 1997 272 : 17196 203.
224. Subbaramaiah K, Chung WJ, Dannenberg AJ. Ceramide regulates the transcription of cyclooxygenase- 2. J Biol Chem. 1998 273 : 32943 9.
225. Hirabayashi T, Murayama T, Shimizu T. Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biol Pharm Bull. 2004 27 : 1168 73.
226. Taketo MM, Sonoshita M. Phospholipase A2 and apoptosis. Biochim Biophys Acta. 2002 1585 : 72 6.
227. Takaku K, Sonoshita M, Sasaki N, Uozumi N, Doi Y, Shimizu T, Taketo MM. Suppression of intestinal polyposis in Apc (delta 716) knockout mice by an additional mutation in the cytosolic phospholipase A(2) gene. J Biol Chem. 2000 275 : 34013 6.
228. Hong KH, Bonventre JC, O'Leary E, Bonventre JV, Lander ES. Deletion of cytosolic phospholipase A2 suppresses ApcMin -induced tumorigenesis. Proc Natl Acad Sci USA. 2001 98 : 3935 9.
229. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2(Cox-2). Cell. 1996 87 : 803 9.
230. Penzo D, Petronilli V, Angelin A, Cusan C, Colonna R, Scorrano L, Pagano F, Prato M, Di Lisa F, Bernardi P. Arachidonic acid released by phospholipase A2 activation triggers Ca2+-dependent apoptosis through the mitochondrial pathway. J Biol Chem. 2004 279 : 25219 25.
231. Dong M, Johnson M, Rezaie A, Ilsley JN, Nakanishi M, Sanders MM, Forouhar F, Levine J, Montrose DC, Giardina C, Rosenberg DW. Cytoplasmic phospholipase A2 levels correlate with apoptosis in human colon tumorigenesis. Clin Cancer Res. 2005 15 : 2265 71.
232. Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem. 1999 274 : 23679 82.
233. Shurequi I, Lippman SM. Lipoxygenase modulation to reverse carcinogenesis. Cancer Res. 2001 61 : 6307 12.
234. Ikawa H, Kamitani H, Calvo BF, Foley JF, Eling TE. Expression of 15-lipoxygenase-1 in human colorectal cancer. Cancer Res. 1999 59 : 360 6.
235. Shureiqi I, Chen D, Lee JJ, Yang P, Newman RA, Brenner DE, Lotan R, Fischer SM, Lippman SM. 15- LOX-1: a novel molecular target of nonsteroidal antiinflammatory drug-induced apoptosis in colorectal cancer cells. J Natl Cancer Inst. 2000 92 : 1136 42.
236. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM, Lippman SM. 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory druginduced apoptosis independently of cyclooxygenase- 2 in colon cancer cells. Cancer Res. 2000 60 : 6846 50.
237. Shureiqi I, Wojno KJ, Poore JA, Reddy RG, Moussalli MJ, Spindler SA, Greenson JK, Normolle D, Hasan AAK, Lawrence TS, Brenner DE. Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers. Carcinogenesis. 1999 20 : 1985 95.
238. Ghosh J, Myers CE. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem Biophys Acta. 1997 235 : 418 23.
239. Ghosh J, Myers CE. Inhibition of arachidonate 5- lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA. 1998 95 : 13182 7.
240. Charlier C, Michaux C. Dual inhibition of cyclooxygenase- 2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur J Med Chem. 2003 38 : 645 59.
241. Thun MJ, Henley SJ, Patrono C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002 94 : 252 66.
242. Ulrich CM, Bigler J, Potter JD. Non-steroidal antiinflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer. 2006 6 : 130 40.
243. Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001 15 : 2742 4.
244. Yu H-G, Huang J-A, Yang Y-N, Huang H, Luo H-S, Yu J-P, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F. The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase- 2 negative colon cancer cells. Eur J Clin Invest. 2002 32 : 838 46.
245. Smith M-L, Hawcroft G, Hull MA. The effect of nonsteroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer. 2000 36 : 664 74.
246. Yin H, Xu H, Zhao Y, Yang W, Cheng J, Zhou Y. Cyclooxygenase-independent effects of aspirin on HT-29 human colon cancer cells, revealed by oligonucleotide microarrays. Biotechnol Lett. 2006 28 : 1263 70.
247. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998 396 : 77 80.
248. Seiler N, Raul F. Polyamines and apoptosis. J Cell Mol Med. 2005 9 : 623 42.
249. Patel AR, Wang JY. Polyamines modulate transcription but not posttranscription of c-myc and c-jun in IEC-6 cells. Am J Physiol. 1997 273 : C1020 9.
250. D'Agostino L, Di Luccia A. Polyamines interact with DNA as molecular aggregates. Eur J Biochem. 2002 269 : 4317 25.
251. Ray RM, McCormack SA, Johnson LR. Polyamine depletion arrests growth of IEC-6 and Caco-2 cells by different mechanisms. Am J Physiol. 2001 281 : G37 G43.
252. Patel AR, Wang J-Y. Polyamine depletion is associated with an increase in JunD/AP-1 activity in small intestinal crypt cells. Am J Physiol. 1999 276 : G441 50.
253. Babbar N, Ignatenko NA, Casero Jr. RA, Gerner EW. Cyclooxygenase- independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem. 2003 278 : 47762 75.
254. Turchanowa L, Dauletbaev N, Milovic V, Stein J. Nonsteroidal anti-inflammatory drugs stimulate spermidine/ spermine acetyltransferase and deplete polyamine content in colon cancer cells. Eur J Clin Invest. 2001 31 : 887 93.
255. Martinez ME, O'Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, Guo Y, Boorman D, Einspahr J, Alberts DS, Gerner EW. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA. 2003 100 : 7859 64.
256. Ignatenko NA, Babbar N, Mehta D, Casero Jr. RA, Gerner EW. Suppession of polyamine catabolism by activated Ki-ras in human colon cancer cells. Mol Carcinog. 2004 39 : 91 102.
257. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome Proliferator-activated receptors α and β are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997 272 : 3406 10.
258. Tsujie M, Nakamori S, Okami J, Hayashi N, Hiraoka N, Nagano H, Dono K, Umeshita K, Sakon M, Monden M. Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator- activated receptor γ/retinoid X receptor α pathway. Exp Cell Res. 2003 289 : 143 51.
259. Panigrahy D, Huang S, Kieran MW, Kaipainen A. PPAR_ as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther. 2005 : 4 : 687 93.
260. Yu H-G, Huang J-A, Yang Y-N, Luo H-S, Yu J-P, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F. Inhibition of cytosolic phospholipase A2 mRNA expression: a novel mechanism for acetylsalicylic acid-mediated growth inhibition and apoptosis in colon cancer cells. Reg Pept. 2003 114 : 101 7.
261. Baek SJ, Kim K-S, Nixon JB, Wilson LC, Eling TE. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol. 2001 59 : 901 8.
262. Hardwick JCH, van Santen M, Van Den Brink GR, van Deventer SJH, Peppelenbosch MP. DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis. 2004 25 : 1293 8.
263. Li, PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, Austin RC, Klamut HJ. Placental TGF-β is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem. 2000 275 : 20127 35.
264. Tan M, Wang Y, Guan K, Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci USA. 2000 97 : 109 14.
265. Rice PL, Washington M, Schleman S, Beard KS, Driggers LJ, Ahnen DJ. Sulindac sulphate inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res. 2003 63 : 616 20.
266. Rice PL, Goldberg RJ, Ray EC, Driggers LJ, Ahnen DJ. Inhibition of extracellular signal-regulated kinase1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res. 2001 61 : 1541 7.
267. Rice PL, Kelloff J, Sullivan H, Driggers LJ, Beard KS, Kuwada S, Piazza G, Ahnen DJ. Sulindac metabolites induce caspase- and proteasomedependent degradation of β-catenin protein in human colon cancer cells. Mol Cancer Ther. 2003 2 : 885 92.
268. McEntee MF, Chiu C-H, Whelan J. Relationship of β-catenin and bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis. 1999 20 : 635 40.
269. Dihlmann S, Klein S, von Knebel Doeberitz M. Reduction of β-catenin/T-cell transcription factor signaling by aspirin and indomethacin is caused by an increased stabilization of phosphorylated β-catenin. Mol Cancer Ther. 2003 2 : 509 16.
270. Reid G, Wielinga P, Zelcer N, Van Der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. Proc Natl Acad Sci USA. 2003 100 : 9244 9.
271. Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res. 2003 9 : 383 90.
272. Seno H, Oshima M, Ishikawa T, Oshima H, Takaku K, Chiba T, Narumiya S, Taketo MM. Cyclooxygenase 2- and prostaglandin E2 receptor EP2-dependent angiogenesis in ApcΔ716 mouse intestinal polyps. Cancer Res. 2002 62 : 506 11.
273. Yu H-G, Li J-Y, Yang Y-N, Luo H-S, Yu J-P, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F. Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer. Cancer Lett. 2003 195 : 43 51.
274. Jones MK, Szabó IL, Kawanaka H, Husain SS, Tarnawski AS. Von Hippel Lindau tumor suppressor and HIF-1α: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis FASEB J. 2002 16 : 264 6.
275. Wang HM, Zhang GY. Indomethacin suppresses growth of colon cancer viainhibition of angiogenesis in vivo. World J Gastroenterol. 2005 11 : 340 3.
276. Abdelrahim M, Safe S. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol. 2005 68 : 317 29.
277. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer. 2005 41 : 2438 48.
278. Levine L. Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells. BMC Pharmacol. 2004 4 : 15.
279. Levine L. Proteolysis negatively regulates agoniststimulated arachidonic acid metabolism. Cell Signal. 1998 10 : 653 9.
280. Rockwell P, Yuan H, Magnusson R. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase- 2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE2. Arch Biochem Biophys. 2000 374 : 325 33.
281. Chen J-J, Huang W-C, Chen C-C. Transcriptional regulation of cyclooxygenase-2 in response to proteasome inhibitors involves reactive oxygen speciesmediated signaling pathway and recruitment of CCAAT/Enhancer-binding protein δ and CREB-binding protein. Mol Biol Cell. 2005 16 : 5579 91.
282. Woo KJ, Park J-W, Kwon TK. Proteasome inhibitorinduced cyclooxygenase-2 expression in Raw264.7 cells is potentiated by inhibition of c-Jun N-terminal kinase activation. Biochem Biophys Res Com. 2006 342 : 1334 40.
283. Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, Degendorfer P, Tsao MS, Nicklee T, Birle D, Wright J, Siu L, Moore M, Oza A. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res. 2005 11 : 5526 33.
284. Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone K, Holubec H, Guillén-Rodriguez JM, Gerner EW. APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis. 1999 20 : 1709 13.
285. Nemoto T, Kubota S, Ishida H, Murata N, Hashimoto D. Ornithine decarboxylase, mitogenactivated protein kinase and matrix metallopro teinase-2 expressions in human colon tumors. World J Gastroenterol. 2005 11 : 3065 9.
286. Babbar N, Gerner EW. Polyamines as modifiers of genetic risk factors in human intestinal cancers. Biochem Soc Trans. 2003 31 : 388 92.
287. Milovic V, Turchanowa L. Polyamines and colon cancer. Biochem Soc Trans. 2003 31 : 381 3.
288. Reddy BS, Rao CV. Chemoprophylaxis of colon cancer. Curr Colorectal Cancer Rep. 2006 2 : 13 19.
289. Li H, Schut HA, Conran P, Kramer PM, Lubet RA, Steele VE, Hawk EE, Kelloff GJ, Pereira MA. Prevention by aspirin and its combination with alphadifluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis. 1999 20 : 425 30.
290. Reddy BS, Patlolla JM, Simi B, Wang SH, Rao CV. Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids. Cancer Res. 2005 65 : 8022 7.
291. Ashktorab H, Dawkins FW, Mohamed R, Larbi D, Smoot DT. Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. Dig Dis Sci. 2005 50 : 1025 32.
292. Cusack JC Jr., Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin Jr. AS. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition. Cancer Res. 2001 61 : 3535 40.
293. Fujita T, Doihara H, Washio K, Kawasaki K, Takabatake D, Takahashi H, Tsukuda K, Ogasawara Y, Shimizu N. Proteasome inhibitor bortezomib increases PTEN expression and enhances trastuzumab-induced growth inhibition in trastuzumab-resistant cells. Anticancer Drugs. 2006 17 : 455 62.
294. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu S-M, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004 22 : 2108 21.
295. Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol. 2005 23 : 5943 9.
296. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002 8 : 2505 11.
297. Choi HJ, Kim HH, Lee HS, Huh GY, Seo SY, Jeong JH, Kim J-M, Yoo YH. Lactacystin augments the sulindac-induced apoptosis in HT-29 cells. Apoptosis. 2003 8 : 301 5.
298. Minami T, Adachi M, Kawamura R, Zhang Y, Shinomura Y, Imai K. Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin Cancer Res. 2005 11 : 5248 56.